Genocea Biosciences Inc. (GNCA) 8.93 $GNCA
Genocea Biosciences' (GNCA) CEO Chip Clark on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 11:12AM CST
GNCA: 8.93 (-0.07)
Genocea Biosciences misses by $0.11
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:11AM CST
GNCA: 8.93 (-0.07)
Genocea Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Thu Feb 12, 7:00AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2014.
GNCA: 8.93 (-0.07)
Genocea to Host Fourth Quarter and Year End 2014 Financial Results Conference Call & Webcast on February 12, 2015
Business Wire - Thu Feb 05, 8:30AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on February 12, 2015 at 9:00 a.m. ET to discuss financial results for the fourth quarter and year end 2014. The presentation, hosted by Genocea President and Chief Executive Officer Chip Clark and Chief Financial Officer Jonathan Poole, will provide an update on the company's recent progress and upcoming milestones.
GNCA: 8.93 (-0.07)
CORRECTING and REPLACING Genocea to Present at the 2015 BIO CEO & Investor Conference
Business Wire - Wed Feb 04, 4:05PM CST
First paragraph, second sentence of release (dated February 2, 2015) has been changed to reflect the correct time of the presentation, which now reads: The presentation is scheduled for Monday, February 9, 2015 at 8:00 a.m. EST in New York, NY. (instead of The presentation is scheduled for Monday, February 9, 2015 at 8:30 a.m. EST in New York, NY).
GNCA: 8.93 (-0.07)
Genocea to Present at the 2015 BIO CEO & Investor Conference
Business Wire - Mon Feb 02, 3:00PM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a company overview at the upcoming 2015 BIO CEO & Investor Conference. The presentation is scheduled for Monday, February 9, 2015 at 8:30 a.m. EST in New York, NY.
GNCA: 8.93 (-0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:47AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), SILC: 46.99 (+0.90), GNCA: 8.93 (-0.07), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), LRN: 16.56 (-0.06), SR: 1.25 (+0.08), DSKY: 11.99 (+0.14), GENE: 8.04 (+1.90), SMLR: 4.54 (+0.20), PFMT: 6.02 (-0.02), QCOM: 70.88 (+0.49), PSTR: 4.63 (+0.14), ENTL: 21.99 (+0.56), ATTU: 9.93 (+0.05), CTP: 6.53 (+0.13), LENS: 6.00 (-0.67), RCON: 2.11 (+0.15)
5 Under-$10 Health Care Stocks Setting Up to Trade Higher
at The Street - Thu Jan 29, 6:00AM CST
These setups often produce monster moves higher in very short time frames.
APT: 2.88 (+0.17), CDNA: 6.30 (-0.14), GNCA: 8.93 (-0.07), IG: 10.57 (-0.12), MEIP: 5.00 (-0.04)
Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes
Business Wire - Wed Jan 07, 7:30AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported that it has completed enrollment in its Phase 2 dose optimization clinical trial for GEN-003 for the treatment of genital herpes. The company expects to report top-line data from the immediate post-vaccination observation period in late Q2 2015.
GNCA: 8.93 (-0.07)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.01), PFNX: 12.45 (+0.29), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), RPTP: 9.05 (-0.40), IBIO: 0.90 (+0.36), ANAC: 40.76 (-0.07), PFE: 34.64 (-0.23), GNCA: 8.93 (-0.07), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Genocea Appoints Eric S. Hoffman as Chief Business Officer
Business Wire - Mon Dec 15, 9:55AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Eric S. Hoffman has joined the company as chief business officer.
GNCA: 8.93 (-0.07)
Epizyme selects Kenneth Bate to board
M2 - Mon Dec 15, 5:49AM CST
Biopharmaceutical company Epizyme (NasdaqGS:EPZM) revealed on Friday that Kenneth Bate has been named to its board of directors.
EPZM: 21.58 (+0.08), GNCA: 8.93 (-0.07)
Agenus: Herpes Competition And Cancer Checkpoint Prospects
William Meyers - at Seeking Alpha - Thu Dec 11, 11:06AM CST
AGEN: 5.03 (-0.01), VICL: 1.01 (-0.01), MRK: 58.81 (-0.07), GNCA: 8.93 (-0.07)
Genocea to Present at Upcoming Investor Conferences
Business Wire - Tue Nov 25, 8:06AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present at the following upcoming conferences:
GNCA: 8.93 (-0.07)
Genocea secures new capital
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 8:40AM CST
HTGC: 15.49 (+0.04), GNCA: 8.93 (-0.07)
Genocea Secures Debt Facility from Hercules Technology Growth Capital of up to $27 Million
Business Wire - Fri Nov 21, 7:30AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) for a term loan of up to $27.0 million.
HTGC: 15.49 (+0.04), GNCA: 8.93 (-0.07)
Genocea Named in Top Places to Work List by The Boston Globe
Business Wire - Thu Nov 13, 10:52AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has been named as one of Boston's Top Places to Work by The Boston Globe.
GNCA: 8.93 (-0.07)
Genocea to Present at the Stifel Nicolaus 2014 Healthcare Conference
Business Wire - Wed Nov 12, 7:02AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the Stifel Nicolaus 2014 Healthcare Conference. The presentation is scheduled for Wednesday, November 19, 2014 at 10:20 a.m. EST in New York, NY.
GNCA: 8.93 (-0.07)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 25.34 (+1.20), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), ADMP: 6.50 (-0.01), GNCA: 8.93 (-0.07)
Genocea Biosciences' (GNCA) CEO Chip Clark on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 11:12AM CST
GNCA: 8.93 (-0.07)
Genocea Biosciences misses by $0.11
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:11AM CST
GNCA: 8.93 (-0.07)
Genocea Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Thu Feb 12, 7:00AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2014.
GNCA: 8.93 (-0.07)
Genocea to Host Fourth Quarter and Year End 2014 Financial Results Conference Call & Webcast on February 12, 2015
Business Wire - Thu Feb 05, 8:30AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on February 12, 2015 at 9:00 a.m. ET to discuss financial results for the fourth quarter and year end 2014. The presentation, hosted by Genocea President and Chief Executive Officer Chip Clark and Chief Financial Officer Jonathan Poole, will provide an update on the company's recent progress and upcoming milestones.
GNCA: 8.93 (-0.07)
CORRECTING and REPLACING Genocea to Present at the 2015 BIO CEO & Investor Conference
Business Wire - Wed Feb 04, 4:05PM CST
First paragraph, second sentence of release (dated February 2, 2015) has been changed to reflect the correct time of the presentation, which now reads: The presentation is scheduled for Monday, February 9, 2015 at 8:00 a.m. EST in New York, NY. (instead of The presentation is scheduled for Monday, February 9, 2015 at 8:30 a.m. EST in New York, NY).
GNCA: 8.93 (-0.07)
Genocea to Present at the 2015 BIO CEO & Investor Conference
Business Wire - Mon Feb 02, 3:00PM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a company overview at the upcoming 2015 BIO CEO & Investor Conference. The presentation is scheduled for Monday, February 9, 2015 at 8:30 a.m. EST in New York, NY.
GNCA: 8.93 (-0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:47AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), SILC: 46.99 (+0.90), GNCA: 8.93 (-0.07), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), LRN: 16.56 (-0.06), SR: 1.25 (+0.08), DSKY: 11.99 (+0.14), GENE: 8.04 (+1.90), SMLR: 4.54 (+0.20), PFMT: 6.02 (-0.02), QCOM: 70.88 (+0.49), PSTR: 4.63 (+0.14), ENTL: 21.99 (+0.56), ATTU: 9.93 (+0.05), CTP: 6.53 (+0.13), LENS: 6.00 (-0.67), RCON: 2.11 (+0.15)
5 Under-$10 Health Care Stocks Setting Up to Trade Higher
at The Street - Thu Jan 29, 6:00AM CST
These setups often produce monster moves higher in very short time frames.
APT: 2.88 (+0.17), CDNA: 6.30 (-0.14), GNCA: 8.93 (-0.07), IG: 10.57 (-0.12), MEIP: 5.00 (-0.04)
Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes
Business Wire - Wed Jan 07, 7:30AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported that it has completed enrollment in its Phase 2 dose optimization clinical trial for GEN-003 for the treatment of genital herpes. The company expects to report top-line data from the immediate post-vaccination observation period in late Q2 2015.
GNCA: 8.93 (-0.07)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.01), PFNX: 12.45 (+0.29), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), RPTP: 9.05 (-0.40), IBIO: 0.90 (+0.36), ANAC: 40.76 (-0.07), PFE: 34.64 (-0.23), GNCA: 8.93 (-0.07), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Genocea Appoints Eric S. Hoffman as Chief Business Officer
Business Wire - Mon Dec 15, 9:55AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Eric S. Hoffman has joined the company as chief business officer.
GNCA: 8.93 (-0.07)
Epizyme selects Kenneth Bate to board
M2 - Mon Dec 15, 5:49AM CST
Biopharmaceutical company Epizyme (NasdaqGS:EPZM) revealed on Friday that Kenneth Bate has been named to its board of directors.
EPZM: 21.58 (+0.08), GNCA: 8.93 (-0.07)
Agenus: Herpes Competition And Cancer Checkpoint Prospects
William Meyers - at Seeking Alpha - Thu Dec 11, 11:06AM CST
AGEN: 5.03 (-0.01), VICL: 1.01 (-0.01), MRK: 58.81 (-0.07), GNCA: 8.93 (-0.07)
Genocea to Present at Upcoming Investor Conferences
Business Wire - Tue Nov 25, 8:06AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present at the following upcoming conferences:
GNCA: 8.93 (-0.07)
Genocea secures new capital
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 8:40AM CST
HTGC: 15.49 (+0.04), GNCA: 8.93 (-0.07)
Genocea Secures Debt Facility from Hercules Technology Growth Capital of up to $27 Million
Business Wire - Fri Nov 21, 7:30AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) for a term loan of up to $27.0 million.
HTGC: 15.49 (+0.04), GNCA: 8.93 (-0.07)
Genocea Named in Top Places to Work List by The Boston Globe
Business Wire - Thu Nov 13, 10:52AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has been named as one of Boston's Top Places to Work by The Boston Globe.
GNCA: 8.93 (-0.07)
Genocea to Present at the Stifel Nicolaus 2014 Healthcare Conference
Business Wire - Wed Nov 12, 7:02AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the Stifel Nicolaus 2014 Healthcare Conference. The presentation is scheduled for Wednesday, November 19, 2014 at 10:20 a.m. EST in New York, NY.
GNCA: 8.93 (-0.07)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 25.34 (+1.20), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), ADMP: 6.50 (-0.01), GNCA: 8.93 (-0.07)
